BRISTOL-MYERS SQUIBB, S.A.U. secures contract for Antineoplastic agents - Environmentally friendly supply of medicines for human use whose active ingredients are mavacamten, fedratinib, abatacept, ipilimumb, nivolumab, luspatercept, cobicistat/atazanavir, deucravanacitinib and ozanimod, destined for Valencian public health centers

Spain, Jan. 2 -- Spain based BRISTOL-MYERS SQUIBB, S.A.U. has secured contract from Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad for Antineoplastic agents - Environmentally friendly supply of medicines for human use whose active ingredients are mavacamten, fedratinib, abatacept, ipilimumb, nivolumab, luspatercept, cobicistat/atazanavir, deucravanacitinib and ozanimod, destined for Valencian public health centers. The value of the contract is not disclosed.

Published by HT Digital Content Services with permission from Pivotal Sources....